MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Which Esophageal Cancer Patient Will Respond To Treatment

Back to esophageal Blogs list Cancer blog  


Subscribe To Esophageal RSS Feed  RSS content feed What is RSS feed?

Which Esophageal Cancer Patient Will Respond To Treatment

Which Esophageal Cancer Patient Will Respond To Treatment
New research at Wake Forest University Baptist Medical Center shows that Positron Emission Tomography (PET) is more accurate than conventional imaging in identifying patients who have good responses to chemotherapy and radiation therapy -- a finding that could one day help some patients avoid surgery.

The results, from a study of 64 patients with esophageal cancer, are reported in the recent issue of Annals of Surgery. PET, a technology that produces images of the metabolic function of tissue, was used to test patients for cancer after therapy with a combination of chemotherapy and radiation (chemoradiation).

"While additional multi-center studies are needed, the research clearly shows that PET is a useful tool for identifying patients who respond well to chemoradiation," said Edward A. Levine, M.D., lead investigator. "Being able to identify these responders may alter the need to take some patients to surgery."

Over the past two decades, the most common therapy for esophageal cancer has been chemoradiation followed by surgery. Even with these therapys, the prognosis is poor for most patients, with long-term control rates of 25 to 35 percent. Some patients, however, respond well to chemoradiation and have improved long-term survival.

Identifying which patients will respond to chemoradiation alone -- and perhaps avoid surgery to remove part of the esophagus -- has been difficult. Conventional imaging, including both computed tomography (CT) and endoscopic ultrasound (EUS), are poor predictors of response to chemoradiation.

Recently, PET was shown to be more accurate than CT and EUS in evaluating newly diagnosed patients to determine the extent of the disease. So, Wake Forest scientists decided to evaluate its ability to determine response to chemoradiation.

"The technology has allowed us to evaluate the varying responses to chemoradiation in a cross-section of patients," said Levine, professor of surgery and chief of the Section of Surgical Oncology. "We have identified a subgroup of patients with good long-term control rates and improved long-term survival."

The scientists conducted the study between 2000 and 2004 in patients whose cancer had not spread beyond the esophagus and lymph nodes. Patients had a PET scan both before and after chemoradiation. Then, four to six weeks later, eligible patients had surgery to remove part of the esophagus. The surgical pathology reports from 41 patients were compared to PET results -- and PET was found to be 88 percent accurate at correctly identifying patients without disease.

"These results show the predictive power of pre-treatment PET imaging for identifying patients likely to experience a significant tumor response following a course of pre-operative chemoradiation," said Levine. "The evidence suggests the potential for PET to change clinical practice, perhaps helping some patients avoid surgery".

This study was supported, in part, by a grant from the National Cancer Institute.



Posted by: Sue    Source




Did you know?
New research at Wake Forest University Baptist Medical Center shows that Positron Emission Tomography (PET) is more accurate than conventional imaging in identifying patients who have good responses to chemotherapy and radiation therapy -- a finding that could one day help some patients avoid surgery.

Medicineworld.org: Which Esophageal Cancer Patient Will Respond To Treatment

Esophageal cancer info| Diagnosis of esophageal cancer| Follow of esophageal cancer| Esophageal cancer resources| Risk factors for esophageal cancer| Screening for esophageal cancer| Symptoms of esophageal cancer| Treatment of esophageal cancer|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.